CD20⁺ T Cells as Pathogenic Players and Therapeutic Targets in MS

Ann Neurol. 2021 Nov;90(5):722-724. doi: 10.1002/ana.26232. Epub 2021 Oct 8.

Authors

Edgar Meinl^{1

2}, Reinhard Hohlfeld^{1

2

3}

Affiliations

¹ Institute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
² Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
³ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

PMID: 34585761
DOI: 10.1002/ana.26232

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD20 / immunology*
Antigens, CD20 / metabolism
B-Lymphocytes / drug effects
Humans
Rituximab / therapeutic use*
T-Lymphocytes / drug effects*
T-Lymphocytes / pathology*

Substances

Antigens, CD20
Rituximab

Grants and funding